Single-Use Spray Takes Aim at GI Bleeds

Cook Medical concluded a 10-year-journey this week after it received approval of its Hemospray in the U.S. to treat gastrointestinal bleeds.

Omar Ford

May 8, 2018

2 Min Read
Single-Use Spray Takes Aim at GI Bleeds
Courtesy of Cook Medical

Cook Medical has been focused on finding an easier way to treat patients suffering from gastrointestinal bleeds. For nearly 10 years the Bloomington IN-based company has been developing the Hemospray, a powder like device that has just received a nod from FDA.

Barry Slowey, VP of Cook Medical’s Endoscopy specialty, said the company got the idea for Hemospray from an application used by the U.S. military in Afghanistan and Iraq to treat wounds on the battlefield.

“If you look at the how bleeds are treated in the gastrointestinal tract, you see  the treatments are either mechanical, like an endoscopic clip that closes off an artery, or it’s a heater probe to burn it," Slowey told MD+DI. "We were trying to think of a better way to do it. We came up with the concept of using a spray.”

Thermal, mechanical or contact devices can carry a risk of further tissue damage and require precise placement of the device directly onto the bleeding vessel. However, Cook said Hemospray can reduce the risk of tissue damage. The device delivers hemostatic powder through the channel of an endoscope toward the source of a bleed. When the powder comes in contact with blood, it absorbs water and forms a gel, which acts cohesively and adhesively to create a stable mechanical barrier that covers the bleeding site.

The company has had approval for Hemospray outside of the U.S. since 2011.

Numerous reports in the clinical literature have demonstrated the clinical utility of Hemospray when used alone or with other methods. In a summary of 19 studies of Hemospray comprising treatment of 234 patients, the combined rate of successful hemostasis was 88.5%. Rebleeding occurred within 72 hours in 16.2% after successful initial hemostasis with Hemospray.

“We were able to put together a clinical evidence report from FDA which included 560 published cases over a number of papers across the world,” Slowey said. “In addition to those cases, we were also able to include the data from three Cook sponsored studies.”

About the Author

Omar Ford

Omar Ford is a veteran reporter in the field of medical technology and healthcare journalism. As Editor-in-Chief of MD+DI (Medical Device and Diagnostics Industry), a leading publication in the industry, Ford has established himself as an authoritative voice and a trusted source of information.

Ford, who has a bachelor's degree in print journalism from the University of South Carolina, has dedicated his career to reporting on the latest advancements and trends in the medical device and diagnostic sector.

During his tenure at MD+DI, Ford has covered a wide range of topics, including emerging medical technologies, regulatory developments, market trends, and the rise of artificial intelligence. He has interviewed influential leaders and key opinion leaders in the field, providing readers with valuable perspectives and expert analysis.

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like